Pregnancy outcomes in women with epilepsy: A systematic review and meta-analysis of published pregnancy registries and cohorts

Epilepsy Research

Volumn 81, Issue 1, 2008, Pages 1-13

  Meador, Kimford ^a   Reynolds, Matthew W ^b   Crean, Sheila ^b   Fahrbach, Kyle ^b   Probst, Corey ^b  

^a UNIVERSITY OF FLORIDA   (United States)

^b UNITED BIOSOURCE CORPORATION   (United States)

Author keywords

Anti epileptic drugs; Anticonvulsants; Congenital malformations; Epilepsy; Fetus; Pregnancy

Indexed keywords

CARBAMAZEPINE; LAMOTRIGINE; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; VALPROATE CALCIUM; VALPROATE SEMISODIUM; VALPROIC ACID;

ADVERSE OUTCOME; CLINICAL TRIAL; CONGENITAL MALFORMATION; EPILEPSY; HUMAN; META ANALYSIS; MONOTHERAPY; MORBIDITY; PREGNANCY OUTCOME; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SPONTANEOUS ABORTION; SYSTEMATIC REVIEW;

ABNORMALITIES, DRUG-INDUCED; ADULT; ANTICONVULSANTS; COHORT STUDIES; DATA INTERPRETATION, STATISTICAL; DATABASES, FACTUAL; DRUG THERAPY, COMBINATION; EPILEPSY; FEMALE; HUMANS; INFANT, NEWBORN; MALE; MEDLINE; PREGNANCY; PREGNANCY COMPLICATIONS; REGISTRIES; RISK FACTORS;

EID: 50649120140     PISSN: 09201211     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eplepsyres.2008.04.022     Document Type: Review

References (98)

1. In: Alderson P., Green S., and Higgins J.P.T. (Eds). Cochrane Collaboration Handbook 4.2.1, The Cochrane Library, Issue 1 (2004), John Wiley & Sons Ltd., Chichester, UK (updated December 2003)
2. Annegers J.F., Hauser W.A., Elveback L.R., Anderson V.E., and Kurland L.I. Congenital malformations and seizure disorders in the offspring of parents with epilepsy. Int. J. Epidemiol. 7 (1978) 241-247
3. Annegers J.F., Baumgartner K.B., Hauser W.A., and Kurland L.T. Epilepsy, antiepileptic drugs, and the risk of spontaneous abortion. Epilepsia 29 (1988) 451-458
4. Artama M., Auvinen A., Raudaskoski T., Isojarvi I., and Isojarvi J. Antiepileptic drug use of women with epilepsy and congenital malformations in offspring. Neurology 64 (2005) 1874-1878
5. Artama M., Ritvanen A., Gissler M., Isojarvi J., and Auvinen A. Congenital structural anomalies in offspring of women with epilepsy-a population-based cohort study in Finland. Int. J. Epidemiol. 35 (2005) 280-287
6. Battino D., Binelli S., Caccamo M.L., Canevini M.P., Canger R., Como M.L., et al. Malformations in offspring of 305 epileptic women: a prospective study. Acta Neurol. Scand. 85 (1992) 204-207
7. Battino D., Kaneko S., Andermann E., Avanzini G., Canevini M.P., Canger R., et al. Intrauterine growth in the offspring of epileptic women: a prospective multicenter study. Epilepsy Res. 36 (1999) 53-60
8. Bertollini R., Kallen B., Mastroiacovo P., and Robert E. Anticonvulsant drugs in monotherapy. Effect on the fetus. Eur. J. Epidemiol. 3 (1987) 164-171
9. Bjerkedal T., and Bahna S.L. The course and outcome of pregnancy in women with epilepsy. Acta Obstet. Gynecol. Scand. 52 (1973) 245-248
10. Canger R., Battino D., Canevini M.P., Fumarola C., Guidolin L., Vignoli A., et al. Malformations in offspring of women with epilepsy: a prospective study. Epilepsia 40 (1999) 1231-1236
11. Cook D.J., Mulrow C.D., and Haynes R.B. Systematic reviews: synthesis of best evidence for clinical decisions. Ann. Intern. Med. 126 (1997) 376-380
12. Cunnington M.C. The international lamotrigine pregnancy registry update for the epilepsy foundation. Epilepsia 45 (2004) 1468
13. Cunnington M., and Tennis P. Lamotrigine and the risk of malformations in pregnancy. Neurology 64 (2005) 955-960
14. Czeizel A.E., Bod M., and Halasz P. Evaluation of anticonvulsant drugs during pregnancy in a population-based Hungarian study. Eur. J. Epidemiol. 8 (1992) 122-127
15. Diav-Citrin O., Shechtman S., Arnon J., and Ornoy A. Is carbamazepine teratogenic? A prospective controlled study of 210 pregnancies. Neurology 57 (2001) 321-324
16. Dravet C., Julian C., Legras C., Magaudda A., Guerrini R., Genton P., et al. Epilepsy, antiepileptic drugs, and malformations in children of women with epilepsy: a French prospective cohort study. Neurology 42 (1992) 75-82
17. D'Souza S.W., Robertson I.G., Donnai D., and Mawer G. Fetal phenytoin exposure, hypoplastic nails, and jitteriness. Arch. Dis. Child. 66 (1991) 320-324
18. Eskazan E., and Aslan S. Antiepileptic therapy and teratogenicity in Turkey. Int. J. Clin. Pharmacol. Ther. Toxicol. 30 (1992) 261-264
19. Fairgrieve S.D., Jackson M., Jonas P., Walshaw D., White K., Montgomery T.L., et al. Population based, prospective study of the care of women with epilepsy in pregnancy. BMJ 321 (2000) 674-675
20. Fedrick J. Epilepsy and pregnancy: a report from the Oxford Record Linkage Study. Br. Med. J. 2 (1973) 442-448
21. Fonager K., Larsen H., Pedersen L., and Sorensen H.T. Birth outcomes in women exposed to anticonvulsant drugs. Acta Neurol. Scand. 101 (2000) 289-294
22. German J., Kowal A., and Ehlers K.H. Trimethadione and human teratogenesis. Teratology 3 (1970) 349-362
23. Higgins T.A., and Comerford J.B. Epilepsy in pregnancy. J. Ir. Med. Assoc. 67 (1974) 317-320
24. Hiilesmaa V.K., Teramo K., Granstrom M.L., and Bardy A.H. Fetal head growth retardation associated with maternal antiepileptic drugs. Lancet 2 (1981) 165-167
25. Hiilesmaa V.K., Teramo K., Granstrom M.L., and Bardy A.H. Serum folate concentrations during pregnancy in women with epilepsy: relation to antiepileptic drug concentrations, number of seizures, and fetal outcome. Br. Med. J. (Clin. Res. Ed.) 287 (1983) 577-579
26. Hiilesmaa V.K., Bardy A., and Teramo K. Obstetric outcome in women with epilepsy. Am. J. Obstet. Gynecol. 152 (1985) 499-504
27. Holmes L.B., and Wyszynski D.F. North American antiepileptic drug pregnancy registry. Epilepsia 45 (2004) 1465
28. Holmes L.B., Harvey E.A., Brown K.S., Hayes A.M., and Khoshbin S. Anticonvulsant teratogenesis. I. A study design for newborn infants. Teratology 49 (1994) 202-207
29. Holmes L.B., Harvey E.A., Coull B.A., Huntington K.B., Khoshbin S., Hayes A.M., et al. The teratogenicity of anticonvulsant drugs. N. Engl. J. Med. 344 (2001) 1132-1138
30. Holmes L.B., Wyszynski D.F., and Lieberman E. The AED (antiepileptic drug) pregnancy registry: a 6-year experience. Arch. Neurol. 61 (2004) 673-678
31. Hunt S., Craig J., Russell A., Guthrie E., Parsons L., Robertson I., et al. Levetiracetam in pregnancy: preliminary experience from the UK Epilepsy and Pregnancy Register. Neurology 67 (2006) 1876-1879
32. Hvas C.L., Henriksen T.B., Ostergaard J.R., and Dam M. Epilepsy and pregnancy: effect of antiepileptic drugs and lifestyle on birthweight. BJOG 107 (2000) 896-902
33. Jick S.S., and Terris B.Z. Anticonvulsants and congenital malformations. Pharmacotherapy 17 (1997) 561-564
34. Kaaja E., Kaaja R., Matila R., and Hiilesmaa V. Enzyme-inducing antiepileptic drugs in pregnancy and the risk of bleeding in the neonate. Neurology 58 (2002) 549-553
35. Kaaja E., Kaaja R., and Hiilesmaa V. Major malformations in offspring of women with epilepsy. Neurology 60 (2003) 575-579
36. Kallen B. A register study of maternal epilepsy and delivery outcome with special reference to drug use. Acta Neurol. Scand. 73 (1986) 253-259
37. Kallen A.J. Maternal carbamazepine and infant spina bifida. Reprod. Toxicol. 8 (1994) 203-205
38. Källín B. Maternal drug use and infant cleft lip/palate with special reference to corticoids. Cleft Palate Craniofac. J. 40 (2003) 624-628
39. Kaneko S., Otani K., Fukushima Y., Ogawa Y., Nomura Y., Ono T., et al. Teratogenicity of antiepileptic drugs: analysis of possible risk factors. Epilepsia 29 (1988) 459-467
40. Kaneko S., Otani K., Kondo T., Fukushima Y., Nakamura Y., Ogawa Y., et al. Malformation in infants of mothers with epilepsy receiving antiepileptic drugs. Neurology 42 (1992) 68-74
41. Kaneko S., Otani K., Kondo T., Fukushima Y., Kan R., Takeda A., et al. Teratogenicity of antiepileptic drugs and drug specific malformations. Jpn. J. Psychiat. Neurol. 47 (1993) 306-308
42. Kaneko S., Battino D., Andermann E., Wada K., Kan R., Takeda A., et al. Congenital malformations due to antiepileptic drugs. Epilepsy Res. 33 (1999) 145-158
43. Katz J.M., Pacia S.V., and Devinsky O. Current management of epilepsy and pregnancy: fetal outcome, congenital malformations, and developmental delay. Epilepsy Behav. 2 (2001) 119-123
44. King P.B., Lie R.T., and Irgens L.M. Spina bifida and cleft lip among newborns of Norwegian women with epilepsy: changes related to the use of anticonvulsants. Am. J. Public Health 86 (1996) 1454-1456
45. Knight A.H., and Rhind E.G. Epilepsy and pregnancy: a study of 153 pregnancies in 59 patients. Epilepsia 16 (1975) 99-110
46. Koch S., Losche G., Jager-Roman E., Jakob S., Rating D., Deichl A., et al. Major and minor birth malformations and antiepileptic drugs. Neurology 42 (1992) 83-88
47. Lander C.M., and Eadie M.J. Antiepileptic drug intake during pregnancy and malformed offspring. Epilepsy Res. 7 (1990) 77-82
48. Lindhout D., Hoppener R.J., and Meinardi H. Teratogenicity of antiepileptic drug combinations with special emphasis on epoxidation (of carbamazepine). Epilepsia 25 (1984) 77-83
49. Lindhout D., Meinardi H., Meijer J.W., and Nau H. Antiepileptic drugs and teratogenesis in two consecutive cohorts: changes in prescription policy paralleled by changes in pattern of malformations. Neurology 42 (1992) 94-110
50. Lowe C.R. Congenital malformations among infants born to epileptic women. Lancet 1 (1973) 9-10
51. Martin P.J., and Millac P.A. Pregnancy, epilepsy, management and outcome: a 10-year perspective. Seizure 2 (1993) 277-280
52. Mastroiacovo P., Bertollini R., and Licata D. Fetal growth in the offspring of epileptic women: results of an Italian multicentric cohort study. Acta Neurol. Scand. 78 (1988) 110-114
53. Meador K.J., Baker G.A., Finnell R.H., Kalayjian L.A., Liporace J.D., Loring D.W., et al. In utero antiepileptic drug exposure: fetal death and malformations. Neurology 67 (2006) 407-412
54. Meischenguiser R., D'Giano C.H., and Ferraro S.M. Oxcarbazepine in pregnancy: clinical experience in Argentina. Epilepsy Behav. 5 (2004) 163-167
55. Monson R.R., Rosenberg L., Hartz S.C., Shapiro S., Heinonen O.P., and Slone D. Diphenylhydantoin and selected congenital malformations. N. Engl. J. Med. 289 (1973) 1049-1052
56. Morrow J., Russell A., Guthrie E., Parsons L., Robertson I., Waddell R., et al. Malformation risks of antiepileptic drugs in pregnancy: a prospective study from the UK Epilepsy and Pregnancy Register. J. Neurol. Neurosurg. Psychiatry 77 (2006) 193-198
57. Mullers-Kuppers V.M. Embryopathy during pregnancy caused by taking anticonvulsants. Acta Paedopsychiatr. 30 (1963) 401-405
58. Nakane Y. Congenital malformation among infants of epileptic mothers treated during pregnancy-the report of a collaborative study group in Japan. Folia Psychiatr. Neurol. Jpn. 33 (1979) 363-369
59. Nakane Y., Okuma T., Takahashi R., Sato Y., Wada T., Sato T., et al. Multi-institutional study on the teratogenicity and fetal toxicity of antiepileptic drugs: a report of a collaborative study group in Japan. Epilepsia 21 (1980) 663-680
60. Nelson K.B., and Ellenberg J.H. Maternal seizure disorder, outcome of pregnancy, and neurologic abnormalities in the children. Neurology 32 (1982) 1247-1254
61. Niswander J.D., and Wertelecki W. Congenital malformation among offspring of epileptic women. Lancet 1 (1973) 1062
62. Oguni M., Dansky L., Andermann E., Sherwin A., and Andermann F. Improved pregnancy outcome in epileptic women in the last decade: relationship to maternal anticonvulsant therapy. Brain Dev. 14 (1992) 371-380
63. Olafsson E., Hallgrimsson J.T., Hauser W.A., Ludvigsson P., and Gudmundsson G. Pregnancies of women with epilepsy: a population-based study in Iceland. Epilepsia 39 (1998) 887-892
64. Omtzigt J.G., Los F.J., Grobbee D.E., Pijpers L., Jahoda M.G., Brandenburg H., et al. The risk of spina bifida aperta after first-trimester exposure to valproate in a prenatal cohort. Neurology 42 (1992) 119-125
65. Omtzigt J.G., Los F.J., Hagenaars A.M., Stewart P.A., Sachs E.S., and Lindhout D. Prenatal diagnosis of spina bifida aperta after first-trimester valproate exposure. Prenat. Diagn. 12 (1992) 893-897
66. Omtzigt J.G., Los F.J., Meijer J.W., and Lindhout D. The 10,11-epoxide-10,11-diol pathway of carbamazepine in early pregnancy in maternal serum, urine, and amniotic fluid: effect of dose, comedication, and relation to outcome of pregnancy. Ther. Drug Monit. 15 (1993) 1-10
67. Pilo C., Wide K., and Winbladh B. Pregnancy, delivery, and neonatal complications after treatment with antiepileptic drugs. Acta Obstet. Gynecol. Scand. 85 (2006) 643-646
68. Reiff-Eldridge R., Heffner C.R., Ephross S.A., Tennis P.S., White A.D., and Andrews E.B. Monitoring pregnancy outcomes after prenatal drug exposure through prospective pregnancy registries: a pharmaceutical company commitment. Am. J. Obstet. Gynecol. 182 (2000) 159-163
69. Richmond J.R., Krishnamoorthy P., Andermann E., and Benjamin A. Epilepsy and pregnancy: an obstetric perspective. Am. J. Obstet. Gynecol. 190 (2004) 371-379
70. Robert E., Lofkvist E., Mauguiere F., and Robert J.M. Evaluation of drug therapy and teratogenic risk in a Rhone-Alpes district population of pregnant epileptic women. Eur. Neurol. 25 (1986) 436-443
71. Sabers A., aRogvi-Hansen B., Dam M., Fischer-Rasmussen W., Gram L., Hansen M., et al. Pregnancy and epilepsy: a retrospective study of 151 pregnancies. Acta Neurol. Scand. 97 (1998) 164-170
72. Sabers A., Dam M., A-Roqvi-Hansen B., Boas J., Sidenius P., Laue Friis M., et al. Epilepsy and pregnancy: lamotrigine as main drug used. Acta Neurol. Scand. 109 (2004) 9-13
73. Samren E.B., van Duijn C.M., Christiaens G.C., Hofman A., and Lindhout D. Antiepileptic drug regimens and major congenital abnormalities in the offspring. Ann. Neurol. 46 (1999) 739-746
74. Sawhney H., Vasishta K., Suri V., Khunnu B., Goel P., and Sawhney I.M.S. Pregnancy with epilepsy-a retrospective analysis. Int. J. Gynaecol. Obstet. 54 (1996) 17-22
75. Schupf N., and Ottman R. Reproduction among individuals with idiopathic/cryptogenic epilepsy: risk factors for spontaneous abortion. Epilepsia 38 (1997) 824-829
76. Shakir R.A., and Abdulwahab B. Congenital malformations before and after the onset of maternal epilepsy. Acta Neurol. Scand. 84 (1991) 153-156
77. Shapiro S., Hartz S.C., Siskind V., Mitchell A.A., Slone D., Rosenberg L., et al. Anticonvulsants and parental epilepsy in the development of birth defects. Lancet 1 (1976) 272-275
78. Sonneveld S.W., and Correy J.F. Outcome of pregnancies complicated by epilepsy in Tasmania 1981-1988. Aust. N. Z. J. Obstet. Gynaecol. 30 (1990) 286-289
79. Speidel B.D., and Meadow S.R. Maternal epilepsy and abnormalities of the fetus and newborn. Lancet 2 (1972) 839-843
80. Starreveld-Zimmerman A.A.E., van der Kolk W.J., Elshove J., and Meinardi H. Teratogenicity of antiepileptic drugs. Clin. Neurol. Neurosurg. 2 (1974) 81-95
81. Steegers-Theunissen R.P., Renier W.O., Borm G.F., Thomas C.M., Merkus H.M., Op de Coul D.A., et al. Factors influencing the risk of abnormal pregnancy outcome in epileptic women: a multi-centre prospective study. Epilepsy Res. 18 (1994) 261-269
82. Tanganelli P., and Regesta G. Epilepsy, pregnancy, and major birth anomalies: an Italian prospective, controlled study. Neurology 42 (1992) 89-93
83. Tennis P., and Eldridge R.R. Preliminary results on pregnancy outcomes in women using lamotrigine. Epilepsia 43 (2002) 1161-1167
84. Tomson T. Seizure control and treatment in pregnancy-observations from the EURAP Epilepsy Pregnancy Registry. Neurology 66 (2006) 354-360
85. Tomson T., Battino D., Bonizzoni E., Craig J., Lindhout D., Perucca E., et al. EURAP: an international registry of antiepileptic drugs and pregnancy. Epilepsia 45 (2004) 1463-1464
86. Vajda F.J., and Eadie M.J. Maternal valproate dosage and foetal malformations. Acta Neurol. Scand. 112 (2005) 137-143
87. Vajda F.J., O'Brien T.J., Hitchcock A., Graham J., and Lander C. The Australian registry of anti-epileptic drugs in pregnancy: experience after 30 months. J. Clin. Neurosci. 10 (2003) 543-549
88. Vajda F., Lander C., O'Brien T.J., Hitchcock A., Graham J., et al. Australian pregnancy registry of women taking antiepileptic drugs. Epilepsia 45 (2004) 1466
89. Vajda F.J., O'Brien T.J., Hitchcock A., Graham J., Cook M., Lander C., et al. Critical relationship between sodium valproate dose and human teratogenicity: results of the Australian register of anti-epileptic drugs in pregnancy. J. Clin. Neurosci. 11 (2004) 854-858
90. Vajda F.J., Hitchcock A., Graham J., Solinas C., O'Brien T.J., Lander C.M., et al. Foetal malformations and seizure control: 52 months data of the Australian Pregnancy Registry. Eur. J. Neurol. 13 (2006) 645-654
91. Viinikainen K., Heinonen S., Eriksson K., and Kalviainen R. Community-based, prospective, controlled study of obstetric and neonatal outcome of 179 pregnancies in women with epilepsy. Epilepsia 47 (2006) 186-192
92. Viinikainen K., Eriksson K., Monkkonen A., Aikia M., Nieminen P., Heinonen S., et al. The effects of valproate exposure in utero on behavior and the need for educational support in school-aged children. Epilepsy Behav. 9 (2006) 636-640
93. Waters C.H., Belai Y., Gott P.S., Shen P., and De Giorgio C.M. Outcomes of pregnancy associated with antiepileptic drugs. Arch. Neurol. 51 (1994) 250-253
94. Wide K., Winbladh B., and Kallen B. Major malformations in infants exposed to antiepileptic drugs in utero, with emphasis on carbamazepine and valproic acid: a nation-wide, population-based register study. Acta Paediatr. 93 (2004) 174-176
95. Wilhelm J., Morris D., and Hotham N. Epilepsy and pregnancy-a review of 98 pregnancies. Aust. N. Z. J. Obstet. Gynaecol. 30 (1990) 290-295
96. Wladimiroff J.W., Stewart P.A., Reuss A., van Swaay E., Lindhout D., and Sachs E.S. The role of ultrasound in the early diagnosis of fetal structural defects following maternal anticonvulsant therapy. Ultrasound Med. Biol. 14 (1988) 657-660
97. Wyszynski D.F., Nambisan M., Surve T., Alsdorf R.M., Smith C.R., and Holmes L.B. Increased rate of major malformations in offspring exposed to valproate during pregnancy. Neurology 64 (2005) 961-965
98. Yerby M.S. Fetal death, malformations and infant mortality in infants of mothers with epilepsy. Epilepsia 37 (1996) 98